Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rachel Bowers

Physician Assistant, Medical Las Vegas, NV Physician Assistant

NPI 1093743510 CMS profile 186272

7500 Smoke Ranch Rd, Suite 200, Las Vegas, NV 89128

Open in the dashboard

General payments

$28,608

474 records reported · program years 2021–2025

Research payments

$210

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Bowers of Las Vegas, NV is reported in the CMS Open Payments database as having received $28,608 across 474 general payments and $210 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,547 85
2024 General $5,216 70
2023 General $5,766 108
2023 Research $210 1
2022 General $6,197 124
2021 General $4,883 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Bowers
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Rachel Bowers were reported at $6,547. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Rachel Bowers Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,883 $156 $41–$563 $132
2022 $6,197 $185 $55–$649 $149
2023 $5,766 $199 $58–$717 $160
2024 $5,216 $206 $62–$740 $164
2025 $6,547 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $15,976 77 payments
  2. Allergan Inc. $3,656 21 payments
  3. Astellas Pharma US Inc $1,474 63 payments
  4. Medtronic, Inc. $1,397 28 payments
  5. Sumitomo Pharma America, Inc. $1,101 55 payments
  6. Dendreon Pharmaceuticals LLC $641 24 payments
  7. Urogen Pharma, Inc. $417 18 payments
  8. Janssen Biotech, Inc. $415 16 payments
  9. Boston Scientific Corporation $393 8 payments
  10. Urovant Sciences Inc $374 21 payments
  11. Other $2,766 143 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,150 23 payments
  2. Food and Beverage $9,368 428 payments
  3. Travel and Lodging $3,605 18 payments
  4. Education $485 5 payments
Products named General payments · program years 2021–2025
  1. BOTOX Urology $18,848 52 payments
  2. INTERSTIM $1,397 28 payments
  3. GEMTESA $1,237 61 payments
  4. PROVENGE $641 24 payments
  5. MYRBETRIQ $620 38 payments
  6. BOTOX Botox Therapeutic $448 20 payments
  7. ORGOVYX $447 26 payments
  8. ERLEADA $415 16 payments
  9. Axonics $391 3 payments
  10. JELMYTO $390 17 payments
  11. Other $3,975 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Medtronic, Inc. $210 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,898

Median for Physician Assistant: 241

Drug cost

$290,938

Median for Physician Assistant: $4,110

Branded share of claims

37%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 208 $171,971
Gemtesa Vibegron Brand 71 $59,419
Estradiol Generic 389 $20,232
Methenamine Hippurate Generic 126 $9,767
Solifenacin Succinate Generic 251 $8,646
Progesterone Progesterone, Micronized Brand 111 $4,214
Testosterone Cypionate Generic 44 $3,313
Tamsulosin Hcl Generic 186 $2,709
Yuvafem Estradiol Brand 16 $2,594
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 79 $2,199

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$80,945

Of which drugs: $38,651

Medicare patients

272

Average age 75

Services billed

8,522

205 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 36%
Chronic kidney disease 31%
Ischemic heart disease 29%
Depression 24%
COPD 19%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 36 7,800 $38,651

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $3,916
$3,916 — 7,800
GEMTESA
  • Sumitomo Pharma America, Inc. $419
$419 71 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $186
$186 — —
JELMYTO
  • UROGEN PHARMA, INC. $81
$81 — —
Trelstar
  • Verity Pharmaceuticals Inc. $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record